论文部分内容阅读
据近日出版的《新英格兰医学杂志》(NEJM)发表的一项随机试验结果证实,Imatinib甲磺酸盐(商品名为Gleevec)目前已被认为是首选治疗慢性髓性白血病(CML)的新药。国际干扰素和STI571随机研究(IRIS)小组的Stephen G.Brien博士及其同事报道说,Gleevec是BCR-ABL酪氨酸激酶的选择性抑制剂,在对α-干扰素无反应的慢性CML病人中可产生高效反应。从血液病学和细胞遗传学角度来看,Gleevec对新确诊的慢性CML病人的耐受性以及进展为加速期或母细胞危象的CML的可能性与作为一线治疗的α-干扰素加小剂量阿糖胞苷相比,均处于优势。该项试验研究共对1106例CML患者随机应用Gleevec或α-干扰素加小剂量阿糖胞苷治疗的作用效果进行了比较;对严格标准条件下的治疗失败者
According to a randomized trial published recently by the New England Journal of Medicine (NEJM), Imatinib mesylate, currently marketed as Gleevec, is now considered to be the new drug of choice for the treatment of chronic myelogenous leukemia (CML). Dr. Stephen G. Brien, International Interferon and STI 571 IRIS Group, and colleagues report that Gleevec is a selective inhibitor of BCR-ABL tyrosine kinase in chronic CML patients who are refractory to interferon-alpha Can produce efficient response. From a hematological and cytogenetic point of view, Gleevec’s resistance to newly diagnosed chronic CML patients and the likelihood of progression to accelerated phase or blast crisis in CML are associated with a reduction in alpha interferon as first-line therapy Compared with the dose of cytarabine, all were at an advantage. The pilot study of a total of 1106 cases of CML patients randomized to Gleevec or interferon α-plus small doses of cytarabine treatment effect were compared; treatment of patients under strict standard conditions